LUCD - Lucid Diagnostics Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

LUCD

LUCID DIAGNOSTICS INC.

NASDAQ

$0.64

▼ DOWN 1.86% (-0.01)

KEY STATISTICS

Market Cap$126.29 M

52w High$1.63

52w Low$0.50

Dividend Yield—

Frequency—

P/E-1.72

Volume1.95M

Shares Out.190.77M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Lishan Aklog

COMPENSATION 2026

Salary$300,000

Stock Awards$447,000

Incentive Plan Pay$0

All Other Comp.$0

Total$897,000

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 14, 2021

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

PRICE TARGET

Target High$2.00

Target Low$2.00

Target Median$2.00

Target Consensus$2.00

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.$1.63M

NOV

WED

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

14.91%

HOLDERS

125

TOP 8 OF 125 · RANKED BY POSITION SIZE

Masters Capital Management LLC

Awm Investment Company, Inc.

3.0M sh

$3.02M

Ghisallo Capital Management LLC

3.0M sh

$2.99M

Geode Capital Management, LLC

2.2M sh

$2.58M

PRICE

$0.64 ▼ DOWN 1.86% (−$0.01)

About Lucid Diagnostics Inc.

https://www.luciddx.com ↗

Lucid Diagnostics Inc., a New York-based subsidiary of PAVmed, develops diagnostic tools like EsoGuard and EsoCheck to detect esophageal precancer and cancer in patients with GERD.

INDUSTRY

Medical - Devices

A PRODUCT LUCID DIAGNOSTICS INC. IS KNOWN FOR

EsoGuard Esophageal DNA Test

The EsoGuard Esophageal DNA Test is a non-invasive, FDA-approved screening tool for early detection of esophageal precancer in at-risk GERD patients, enabling earlier intervention and reducing reliance on invasive endoscopy.

COMPETITORS

COMPETITOR

Lucid Diagnostics in 2025

SENTIMENT: + POSITIVE

REGULATORY · SEPTEMBER 2025

Medical Experts Unanimously Support Medicare Coverage for Lucid's EsoGuard Test in Key Advisory Meeting

A Contractor Advisory Committee (CAC) meeting convened by MolDX-participating Medicare Administrative Contractors on September 4, 2025, resulted in unanimous support from medical experts for Medicare coverage of Lucid's EsoGuard Esophageal DNA Test. This event was a significant milestone in the company's pursuit of a positive Local Coverage Determination (LCD), a critical step for securing reimbursement and driving broader adoption of the test.

CAPITAL ALLOCATION · APRIL AND SEPTEMBER 2025 · COMPLETED

Lucid Diagnostics Executes Multiple Equity Raises in 2025 to Extend Operational Runway Amid Push for Broader Reimbursement

In 2025, Lucid Diagnostics made the strategic decision to raise significant capital through multiple public stock offerings. These capital infusions were crucial for funding ongoing operations and extending the company's financial runway into 2026 as it continues to pursue broader insurance reimbursement for its flagship product, the EsoGuard Esophageal DNA Test.